Addex Therapeutics Ltd of Switzerland has reported top-line data from an early trial of an allosteric modulator drug in patients with schizophrenia. The data show that the compound, ADX71149, met its primary objectives of safety and tolerability. ---Subscribe to MedNous to access this article--- Company News Clinical Research
